U.S. FDA Gives Fast Track Status to Dapagliflozin for Patients With Chronic Kidney Disease U.S. FDA Gives Fast Track Status to Dapagliflozin for Patients With Chronic Kidney Disease
AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga (dapagliflozin) to prevent heart and kidney failure in patients with chronic kidney disease (CKD), with and without diabetes.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Diabetes & Endocrinology News Source Type: news
More News: AstraZeneca | Cardiology | Chronic Kidney Disease | Dapagliflozin | Diabetes | Endocrinology | Food and Drug Administration (FDA) | Forxiga | Heart | Intensive Care | Urology & Nephrology